HEPLISAV B; TherVacB
Phase 1Biologic
HEPLISAV B; TherVacB is one of 36 biologic programs targeting Hepatitis B. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Emtriva
GileadApproved
Selzentry
GSKApproved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Cabenuva
GSKApproved
Sunlenca
GileadApproved
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Retrovir
BBp Consulting, Inc
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HEPLISAV B; TherVacB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details